The mitochondria-targeted antioxidant MitoQ modulates oxidative stress, inflammation and leukocyte-endothelium interactions in leukocytes isolated from type 2 diabetic patients  by Escribano-Lopez, Irene et al.
Contents lists available at ScienceDirect
Redox Biology
journal homepage: www.elsevier.com/locate/redox
The mitochondria-targeted antioxidant MitoQ modulates oxidative stress,
inﬂammation and leukocyte-endothelium interactions in leukocytes isolated
from type 2 diabetic patients
Irene Escribano-Lopeza,1, Noelia Diaz-Moralesa,1, Susana Rovira-Llopisa,b,
Arantxa Martinez de Marañona, Samuel Ordenc, Angeles Alvarezc, Celia Bañulsa,b,
Milagros Rochaa,b,c, Michael P. Murphyd, Antonio Hernandez-Mijaresa,b,e, Victor M. Victora,b,c,f,⁎
a Service of Endocrinology, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region
(FISABIO), Valencia, Spain
b Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
c CIBERehd - Department of Pharmacology and Physiology, University of Valencia, Valencia, Spain
d MRC Mitochondrial Biology Unit, Cambridge, United Kingdom
e Department of Medicine, University of Valencia, Valencia, Spain
f Department of Physiology, University of Valencia, Valencia, Spain
A R T I C L E I N F O
Keywords:
Leukocytes
Oxidative stress
Inﬂammation
Endothelium
Type 2 diabetes
MitoQ
A B S T R A C T
It is not known if the mitochondria-targeted antioxidants such as mitoquinone (MitoQ) can modulate oxidative
stress and leukocyte-endothelium interactions in T2D patients.
We aimed to evaluate the beneﬁcial eﬀect of MitoQ on oxidative stress parameters and leukocyte-
endothelium interactions in leukocytes of T2D patients.
The study population consisted of 98 T2D patients and 71 control subjects. We assessed metabolic and
anthropometric parameters, mitochondrial reactive oxygen species (ROS) production, glutathione peroxidase 1
(GPX-1), NFκB-p65, TNFα and leukocyte-endothelium interactions.
Diabetic patients exhibited higher weight, BMI, waist circumference, SBP, DBP, glucose, insulin, HOMA-IR,
HbA1c, triglycerides, hs-CRP and lower HDL-c with respect to controls.
Mitochondrial ROS production was enhanced in T2D patients and decreased by MitoQ. The antioxidant also
increased GPX-1 levels and PMN rolling velocity and decreased PMN rolling ﬂux and PMN adhesion in T2D
patients. NFκB-p65 and TNFα were augmented in T2D and were both reduced by MitoQ treatment.
Our ﬁndings support that the antioxidant MitoQ has an anti-inﬂammatory and antioxidant action in the
leukocytes of T2D patients by decreasing ROS production, leukocyte-endothelium interactions and TNFα
through the action of NFκB. These data suggest that mitochondria-targeted antioxidants such as MitoQ should
be investigated as a novel means of preventing cardiovascular events in T2D patients.
1. Introduction
Type 2 diabetes (T2D) is currently one of the foremost health
concerns, especially in developed countries. T2D is related to obesity
and insulin resistance (IR), but the key mechanisms relating IR and
T2D in obese subjects are yet to be determined. That said, inﬂamma-
tion, enhanced mitochondrial ROS production and the inﬁltration of
leukocytes into the pancreas seem to be implicated [1].
There is considerable evidence that a chronic, low-grade inﬂam-
matory response is ongoing in and actually precedes T2D and related
syndromes [2,3] and this inﬂammation may be due, in part, to the
eﬀects of hyperglycemia or other metabolic abnormalities on white
blood cells [4]. In this sense, it has been demonstrated that there is an
activation of NFκB under IR conditions [5,6]. In this chronic inﬂam-
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matory state, inﬂammatory cells such as leukocytes are vulnerable to
and markedly damaged by hyperglycemia. In fact, these actions can
contribute to the undermined innate immune function and increased
risk of infection among T2D patients [7].
Oxidative stress and mitochondrial impairment have been impli-
cated in the etiology of IR associated with T2D [8,9]. The pathogenesis
of mitochondrial dysfunction in obesity or any diabetes-related disease
is multifactorial, and can also play an important role in pancreatic β
cell failure in T2D [10,11]. Furthermore, it has been demonstrated that
mitochondria undergo biogenesis in response to high levels of glucose,
but the increased biogenesis is insuﬃcient to accommodate a high
metabolic demand [12]. In addition, obesity, which is related to T2D, is
associated to increased levels of free fatty acids, inﬂammation,
mitochondrial ROS and, therefore, oxidative stress [13].
Leukocytes, and in particular polymorphonuclear leukocytes
(PMNs), constitute a critical host defence against infections associated
with T2D. Furthermore, PMNs may contribute to the oxidative stress
and inﬂammation associated with T2D. In fact, the onset of athero-
sclerosis involves the recruitment of leukocytes to the endothelium, a
process that begins when these cells roll over the endothelial cells and
come to a halt, eventually adhering ﬁrmly. In this sense, a potential role
of mitochondrial dynamics and function in the maintenance of
endothelial cell function in T2D has been postulated [14].
In the aforementioned context, therapies that decrease mitochon-
drial oxidative damage could help decrease the deleterious eﬀects of
T2D [11]. Mitoquinone (MitoQ) is a mitochondria-targeted antioxidant
derived from ubiquinone, and is targeted to mitochondria by covalent
attachment to a lipophilic triphenylphosphonium (TPP) cation [15–
17]. Due to the large mitochondrial membrane potential, this cation is
accumulated within the mitochondria inside cells. Mitochondria-tar-
geted antioxidants are protective in vivo against oxidative damage in
diﬀerent pathologies, such as cancer, T2D, cardiovascular and neuro-
degenerative disorders [18–20].
The aim of the current study was to evaluate the eﬀect of MitoQ on
oxidative stress parameters in leukocytes isolated from T2D patients, in
particular the potential regulation of leukocyte-endothelial interactions
and their eﬀects on NFκB.
2. Materials and methods
2.1. Subjects
98 T2D patients attending the Endocrinology and Nutrition Service
of the University Hospital Doctor Peset (Valencia, Spain) and 71
controls adjusted by age and sex were enrolled in this study. T2D
was diagnosed according to the American Diabetes Association's
criteria. Diagnosis was conﬁrmed when a patient fulﬁlled at least one
of the following criteria: (1) levels of fasting serum glucose ≥126 mg/dl
or random serum glucose ≥200 mg/dL on at least two occasions; (2)
HbA1c ≥6.5%; or (3) antidiabetic medication. Subjects with any of the
following conditions were excluded from the study: history of cardio-
vascular disease (including ischemic heart disease, stroke, peripheral
vascular disease, and chronic disease related to cardiovascular risk);
presence of morbid obesity; insulin treatment, autoimmune disease;
and infectious, malignant, organic, haematological or inﬂammatory
disease.
The study protocols were conducted according to the Helsinki
Declaration and approved by the Ethics Committee of the University
Hospital Doctor Peset. All participants underwent the process of
informed consent required by these institutions.
Blood samples were collected in fasting conditions between 8 a.m.
and 10 a.m. Subjects underwent an anthropometric and analytical
assessment in which height (m), weight (kg), body mass index (BMI;
kg/m2), waist circumference (cm), and systolic and diastolic blood
pressure (SBP/DBP; mmHg) were measured.
2.2. Biochemical determinations
Blood was obtained from the antecubital vein and centrifuged
(1300g, 10 min, 4 °C), and biochemical determinations were per-
formed as previously described [21]. By means of an enzymatic
method, total cholesterol, levels of glucose and triglycerides were
determined in serum. Low density lipoprotein (LDL) content was
calculated with Friedewald's formula, and high density lipoprotein
(HDL) levels were obtained using a Beckman LX20 analyzer (Beckman
Corp., CA, US). Insulin levels were determined by immunochemilumi-
nescence, and insulin resistance was estimated using the homeostasis
model assessment of insulin resistance (HOMA-IR=[fasting insulin
(μU/mL)×fasting glucose (mg/dl)]/405). Percentage of HbA1c was
determined with an automatic glycohemoglobin analyzer (Arkray Inc.,
Kyoto, Japan) and high-sensitive C-reactive protein (hs-CRP) levels
were assessed by an immunonephelometric assay.
2.3. Cell isolation
Leukocytes were isolated from heparinized blood samples that had
been incubated with dextran (3%) for 45 min. Supernatant was
collected, placed over Ficoll-Hypaque (GE Healthcare, Uppsala,
Sweden) and spun at 650g for 25 min at room temperature.
Erythrocytes remaining in the pellet were lysed with lysis buﬀer for
5 min at room temperature and centrifuged at 240g. The leukocyte
pellet was then washed and resuspended in Hanks’ balanced salt
solution (HBSS; Sigma Aldrich, MO, US). Cells were counted with a
Scepter 2.0 cell counter (Millipore Iberica, Madrid, Spain) and divided
into diﬀerent samples, one of which was incubated with 0.5 µM of
MitoQ for 30 min, and the other with decyl-TPP in the same condi-
tions.
2.4. Reactive oxygen species production
Mitochondrial ROS production was assessed using the ﬂuorescent
probe MitoSOX (5×10−6 mol/l, 30 min) by ﬂuorometry using a ﬂuor-
escence microscope (IX81; Olympus) coupled to the static cytometry
software “ScanR” (Olympus). Nuclei were visualized with Hoechst
33342. Measures of ﬂuorescence are referred to as % of control.
2.5. Western blot analysis
PMNs isolated from healthy or diabetic patients were resuspended
at a density of 106 cells/mL in 3 mL of complete RPMI (RPMI
supplemented with 10% FBS). For each control or patient two samples
were prepared: the control sample and the treated (0.5 µM MitoQ,
30 min) sample. The non-antioxidant decyl-TPP was also used as a
control compound. In the meantime, two T25 ﬂasks with conﬂuent
HUVEC were washed twice with PBS at 37 °C. Afterwards, PMN cells
(control and MitoQ/TPP) were added to the HUVEC ﬂask and
incubated and shaken for 10 min (up to 130 rpm, mimicking the
leukocyte-endothelium protocol) in a horizontal shaker at a ﬁxed
temperature of 37 °C. Cells were then pelleted and stored at −80 °C
for subsequent determinations. Cell pellets were lysed on ice for 15 min
with cell lysis buﬀer (20 mM HEPES pH 7.5, 400 mM NaCl, 20%
Glycerol, 0.1 mM EDTA, 10 µm Na2MoO4, 0.5% NP-40, 1 mM dithio-
threitol) and protein extraction was performed in the presence of a
protease inhibitor mixture (10 mM NaF, 1 mM NaVO3, 10 mM PNP,
10 mM β-glycerolphosphate) [22]. Protein concentrations were deter-
mined by a BCA protein assay (Thermo Scientiﬁc, IL, US) after 15 min
centrifugation. Protein samples (25 μg) were resolved on 10% acryla-
mide gels and transferred onto nitrocellulose membrane. After block-
ing, membranes were incubated overnight with primary antibodies at
4 °C. The following primary antibodies were used: GPX-1 (Thermo
Fisher), NFκB-p65 (Abcam), TNFα (Abcam) and Actin (Sigma). Blots
were incubated with the secondary antibodies horseradish peroxidase
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(HRP) goat anti-mouse (Thermo Scientiﬁc) and HRP goat anti-rabbit
(Millipore Iberica), and were developed for 2 min with ECL plus
reagent (GE Healthcare) or Supersignal West Femto (Thermo
Scientiﬁc). Visualization was by means of a Fusion FX5 acquisition
system (Vilbert Lourmat, Marne La Valle´e, France). The signals were
analyzed and quantiﬁed by densitometry using Bio1D software (Vilbert
Lourmat) and all values were normalized to actin.
2.6. Leukocyte-endothelium interaction assay
Adhesion assays under ﬂow conditions were carried out using a
parallel plate ﬂow chamber in vitromodel as previously described [21].
Coverslips with conﬂuent HUVEC monolayers were employed to per-
form the adhesion assays. These coverslips were inserted in the bottom
plate of the ﬂow chamber so that a 5×25 mm portion of the endothelial
cells was exposed, and the ﬂow chamber was mounted on an inverted
microscope (Nikon Eclipse TE 2000-S) connected to a camera.
Leukocyte suspensions were drawn across the HUVEC monolayer at
a ﬂow rate of 0.36 mL/min. Real time microscopic images of the ﬂow-
exposed monolayer were recorded for 5 min and examined. Leukocyte
rolling velocity, rolling ﬂux and adhesion were calculated as described
elsewhere [21]. TNFα (10 ng/mL, 4 h) was used as a positive control
for HUVEC, and platelet activating factor (1 µM, 1 h) for leukocytes.
2.7. Data analysis
Data analysis was performed with SPSS 17.0. The values in Tables
are mean ± SD. Bar graphs show mean ± SEM. Comparisons between 2
groups (Table 1) were performed by a Student's t-test for normally
distributed samples, and a Mann–Whitney U test for non-normally
distributed samples. Chi-Square test was used to compare proportions
among groups. Data were compared with a one-way analysis of
variance (ANOVA) followed by a post hoc test. Analysis of covariance
was employed to minimize the potential inﬂuence of BMI. Serum lipid
and biochemical parameter changes were analyzed by means of a
univariate general linear model using BMI as a covariate. Correlations
were calculated using Spearman's correlation coeﬃcient. Signiﬁcant
diﬀerences were considered when p < 0.05.
3. Results
We evaluated 98 T2D patients and 71 control subjects (Table 1).
Diabetic patients exhibited higher weight, BMI, waist circumference,
SBP, DBP, fasting glucose, insulin, HOMA-IR and HbA1c (p < 0.001)
than controls. When data were adjusted by BMI, statistical diﬀerences
remained unchanged. The lipid proﬁle of diabetic subjects was
characterized by higher triglyceride and lower HDL-c levels with
respect to controls (p < 0.001). However, due to the lipid-lowering
treatment received by most of the T2D patients (65% of patients were
taking statins and 6% ezetimibe), levels of total cholesterol and LDL-c
were lower than in controls (p < 0.001). Inﬂammation, measured as hs-
CRP levels, was also more pronounced in diabetic patients vs controls
(p < 0.001). Statistical diﬀerences remained when analyses were ad-
justed by BMI (p < 0.01).
3.1. Mitochondrial ROS and glutathione peroxidase levels
Leukocytes from diabetic patients displayed enhanced levels of
MitoSOX oxidation, which is consistent with an increase in mitochon-
drial ROS production (Fig. 1A, p < 0.01). However, the mitochondrial
targeted antioxidant MitoQ decreased MitoSOX oxidation in diabetic
leukocytes (p < 0.05) to values similar to those in controls. MitoQ did
not alter MitoSOX oxidation in controls (Fig. 1A).
When glutathione peroxidase 1 (GPX-1) was evaluated by western
blot, diﬀerences were not observed between diabetic and control
subjects (Fig. 1B). The presence of MitoQ increased GPX1 levels in
diabetic cell pellets (p < 0.05) with respect to control and diabetic
groups without MitoQ.
None of these oxidative stress parameters were aﬀected by decyl-
TPP treatment (Fig. 1A–B).
3.2. Leukocyte-endothelium interactions
When leukocyte-endothelium interactions were assessed in controls
and T2D patients, a decrease in leukocyte rolling velocity (Fig. 2A, p <
0.001) and an increase in leukocyte rolling ﬂux (Fig. 2B, p < 0.001) and
adhesion (Fig. 2C, p < 0.01) were observed in T2D patients. Those
eﬀects were reversed in the presence of MitoQ, which increased
leukocyte rolling velocity (Fig. 2A, p < 0.05) and reduced leukocyte
rolling ﬂux (Fig. 2B, p < 0.05) and adhesion (Fig. 2C, p < 0.01) in T2D
patients. MitoQ had no eﬀects in controls and decyl-TPP had no eﬀect
on leukocyte-endothelium interactions.
3.3. Levels of NFκB-p65 and TNFα
Diabetic patients showed an increase in NFκB-p65 levels (Fig. 3A,
p < 0.05). MitoQ decreased the levels of NFκB-p65 in those cells
(Fig. 3A, p < 0.05), showing an anti-inﬂammatory eﬀect, and did not
modify NFκB-p65 levels in the control condition. In addition, NFκB-
p65 levels correlated negatively with GPX1 levels (p < 0.05; r=−0.566)
and positively with glucose levels (p < 0.05; r=0.564) and PMN rolling
ﬂux (p < 0.05; r=0.576).
In relation to TNFα levels, there was an increase in diabetic patients
(Fig. 3B, p < 0.05) to a similar extent as that observed with NFκB-p65
levels, and MitoQ again exerted an anti-inﬂammatory eﬀect by redu-
cing TNFα levels (Fig. 3B, p < 0.05). MitoQ did not have any eﬀect on
control pellets. Furthermore, TNFα levels correlate positively with
PMN rolling ﬂux (p < 0.05; r=0.580) and NFκB-p65 (p < 0.001;
r=0.860).
Decyl-TPP treatment did not aﬀect NFκB-p65 or TNFα levels.
Table 1
Baseline characteristics of the study population.
Control T2D p Value BMI-
adjusted p
Value
N 71 98 –
Male % 45.1 51.7 0.452
Age (years) 57.5 ± 8.2 59.1 ± 8.3 0.263
Weight (kg) 70.6 ± 12.0 82.2 ± 13.7 < 0.001
BMI (kg/m2) 25.8 ± 4.0 30.7 ± 4.4 < 0.001
Waist (cm) 88.4 ± 14.3 105.5 ± 10.4 < 0.001
SBP (mmHg) 129 ± 21 143 ± 21 < 0.001 < 0.01
DBP (mmHg) 74 ± 10 83 ± 15 < 0.001 < 0.01
Glucose (mg/dl) 91.6 ± 12.6 146.8 ± 49.4 < 0.001 < 0.001
Insulin (μUI/
mL)
8.43 ± 4.48 15.70 ± 10.91 < 0.001 < 0.001
HOMA-IR 1.99 ± 1.18 5.50 ± 4.19 < 0.001 < 0.001
HbA1c (%) 5.27 ± 0.28 6.97 ± 1.11 < 0.001 < 0.001
Total
cholesterol
(mg/dl)
193.7 ± 39.3 168.8 ± 37.5 < 0.001 < 0.001
HDL-c (mg/dl) 54.4 ± 11.3 45.1 ± 10.7 < 0.001 < 0.001
LDL-c (mg/dl) 121.1 ± 31.7 96.2 ± 32.8 < 0.001 < 0.001
Triglycerides
(mg/dl)
74.0 (59.5; 97.0) 114.0 (87.0;
157.8)
< 0.001 < 0.001
hs-CRP (mg/l) 0.94 (0.46; 2.53) 3.46 (1.37;
5.72)
< 0.001 < 0.001
Data are expressed as mean ± SD for parametric data or as median (25th and 75th
percentiles) for non-parametric data. Means were compared by a Student's t-test for
normally distributed samples and a Mann–Whitney U test for non-normally distributed
samples. Adjustments by BMI were performed by means of a univariate general linear
model. A Chi-Square test was used to compare proportions among groups. HOMA-
IR=fasting insulin (μU/ml) x fasting glucose (mg/dl)/405.
I. Escribano-Lopez et al. Redox Biology 10 (2016) 200–205
202
4. Discussion
In the present study we report an increase in fasting levels of
glucose, insulin, HOMA-IR, triglycerides, HbA1c and hs-CRP in T2D
patients. Given that BMI was also higher in this group, we adjusted the
data for this parameter, obtaining the same results.
Vascular complications and oxidative stress are features of T2D.
Furthermore, oxidative stress is a key event in the immunobiology of
inﬂammatory responses. In previous studies we have shown that
oxidative stress and mitochondrial dysfunction are present in the
leukocytes of T2D patients and are enhanced in patients with vascular
complications [21,23]. In the present study we have determined that
increased mitochondrial ROS production occurs in leukocytes of T2D
patients, suggesting that leukocyte oxidative stress and mitochondrial
function are altered during long-term exposure to glucose.
Several studies have demonstrated that mitochondrial antioxidant
enzymes can protect against oxidant-induced damage under hypergli-
cemic conditions [24,25]. Furthermore, protecting mitochondria seems
to play an important role in arteriogenesis and angiogenesis under
oxidative stress conditions [26]. For these reasons, we believe that
mitochondria-targeted antioxidants can modulate oxidative stress and
may have beneﬁcial eﬀects in T2D. We have used MitoQ because this
compound is biocompatible and can be administered safely in vivo with
no reported toxic eﬀects. In fact, MitoQ can prevent ischemia/reperfu-
sion-induced cardiac dysfunction [27] and also protects against
endothelial dysfunction in in vivo and in vitro models [28,29].
MitoQ has also demonstrated beneﬁcial eﬀects by preventing diabetic
nephropathy in Ins2+/Akita J mice [18], or by modulating muscle lipid
proﬁle and improving mitochondrial respiration in obesogenic diet-fed
rats [30]. However, it has been also demonstrated that TPP+ com-
pounds such as MitoQ can disrupt mitochondrial function at concen-
trations frequently observed in cell culture and that this behaviour is
dependent on the linker group and independent of antioxidant proper-
ties [31].
ROS may have important roles in hyperglycemia-mediated en-
dothelial dysfunction and microvascular complications associated to IR
[32,33]. Indeed, it has been demonstrated that T2D patients have an
increased risk of developing cardiovascular events, which may be
related to oxidative stress [21]. In relation to this, the results of the
present study show that treatment with MitoQ reduces levels of ROS
and increases those of GPX1, thus exhibiting an antioxidant eﬀect.
Indeed, it has been previously demonstrated that MitoQ can reduce
ROS and modulate GPX1 under oxidative stress conditions such as
propionic acidemia [34].
Hypertension and atherosclerosis are inﬂammatory states charac-
terized by leukocyte recruitment to arterial walls [35]. We have used an
Fig. 1. (A) Levels of MitoSox oxidation in controls and T2D patients in presence and absence of MitoQ or decyl-TPP (30 min, 0.5 µM) and representative ﬂuorescence microscopy
images (B) Levels of GPX-1 (25 kDa) measured by Western blot in controls and T2D patients in presence and absence of MitoQ or decyl-TPP (30 min, 0.5 µM). * p < 0.05 and **p <
0.01vs control; ap < 0.05 vs T2D patients.
Fig. 2. Leukocyte/endothelium interactions in T2D patients and control subjects in presence and absence of MitoQ or decyl-TPP (30 min, 0.5 µM). (A) PMN rolling velocity (μmsecond-
1), (B) rolling ﬂux (PMN per minute) and (C) PMN adhesion (PMN per square millimetre). **p < 0.01 and ***p < 0.001 vs control. ap < 0.05 and bp < 0.01 vs T2D patients.
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in vitro system to study this process, in which human leukocytes ﬂow
over a monolayer of human endothelial cells with a shear rate
equivalent to that observed in vivo [36]. This mimics the process of
rolling and adhesion that precedes inﬂammation in vivo, and which is
essential to maintain vascular homeostasis and integrity. If these
interactions are enhanced, endothelial dysfunction and vascular da-
mage associated with many CVD can take place. In previous studies, we
have demonstrated that T2D patients display features of chronic
inﬂammation and enhanced leukocyte-endothelium interactions, and
that these disturbances can be aggravated in the presence of vascular
complications [21–23]. Our ﬁndings show that the inﬂammatory state
is enhanced in T2D patients. In fact, we have witnessed an increase in
PMN rolling ﬂux and adhesion and a decrease in PMN rolling velocity
by which leukocyte-endothelium interactions were induced.
Interestingly, we have seen that treatment with MitoQ increases
PMN rolling velocity and decreases PMN rolling ﬂux and adhesion in
the leukocytes of T2D patients, suggesting a protective cardiovascular
role. Indeed, MitoQ has previously been reported to decrease ischemia-
reperfusion injury in a murine syngeneic heart transplant model [37]
and to decrease features of metabolic syndrome in an ATM+/-/ApoE-/-
mice model [38].
NFκB is a common inﬂammatory factor and plays an important role
in the regulation of cytokines in diabetic nephropathy [39].
Furthermore, NFκB activity is signiﬁcantly increased in T2D patients
with nephropathy compared to those without renal impairment [5,40].
In line with these studies, we report that the expression of p65-NFκB is
increased in T2D patients, thus highlighting the importance of this
transcription factor. In addition, NFκB levels correlate positively with
glucose levels, which conﬁrms that hyperglycemia is closely associated
with inﬂammation. In this sense, a previous study showed that
inhibition of the IKKβ/NFκB pathway improves glucose tolerance in
obese mice, pointing to a central role of this signaling pathway in the
development of T2D [41]. We also found a negative association
between p65-NFκB and GPX1, which was reported in a previous study
in which lack of GPX1 promoted upregulation of p65-NFκB in mouse
aortas [42]. Moreover, we have observed an increase in the proin-
ﬂammatory cytokine TNFα; interestingly, treatment with MitoQ de-
creased the levels of NFκB and, in consequence, those of TNFα. In
relation with this, it has been demonstrated that mitochondria-targeted
antioxidants such as MitoTempol and MitoQ can protect pancreatic β-
cells against oxidative stress by decreasing NFκB activity, promoting
their survival, and increasing insulin secretion in cell models of the
glucotoxicity and glucolipotoxicity associated with T2D [43].
Interestingly, we have seen that both NFκB and TNFα levels correlate
positively with leukocyte rolling ﬂux, highlighting the role of these
proinﬂammatory markers in the atherosclerotic process.
Our study reveals a potential protective role of mitochondrial
targeted antioxidants in the vasculature. However, a larger cohort of
patients would have provided more conclusive observations, especially
with respect to the correlation studies. In addition, a control group with
a similar BMI to that of our T2D patients would have strengthened our
comparisons.
Overall, our ﬁndings provide a better understanding of the patho-
physiological mechanisms occurring in leukocytes/endothelium of T2D
patients. They suggest that increased inﬂammation and oxidative
stress, together with NFκB activation and increased proinﬂammatory
cytokine TNFα, contribute to the enhanced interaction between these
cells, which augments the risk of CVD. Importantly, treatment with
MitoQ modulates these actions, thus preventing oxidative stress and
chronic inﬂammation, which suggests that this compound has potential
beneﬁcial eﬀects for preventing cardiovascular diseases in T2D.
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